Clinical Scorecard: Dry Eye Dx and Tx: Malfunctioning Mucins
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease |
| Key Mechanisms | Involves mucin dysfunction affecting tear film stability and ocular surface health. |
| Target Population | Individuals with dry eye disease, particularly those with mucin-related issues. |
| Care Setting | Ophthalmology clinics and primary care settings. |
Key Highlights
- Mucins are critical for tear film stability and ocular surface protection.
- Mucin deficiency can lead to various ocular surface diseases.
- Current treatment options for mucin-related issues are limited.
- Compounded N-acetylcysteine (NAC) shows promise for mucin quality improvement.
- Pharmaceutical advances are anticipated to enhance mucin therapy.
Guideline-Based Recommendations
Diagnosis
- Assess mucin quality and quantity in patients with dry eye disease.
Management
- Consider topical or oral secretagogues for mucin deficiency.
Monitoring & Follow-up
- Evaluate ocular surface health and mucin characteristics regularly.
Risks
- Oral secretagogues may cause systemic side effects.
Patient & Prescribing Data
Patients with dry eye disease experiencing mucin dysfunction.
Topical options for mucin enhancement are currently unavailable in the U.S.
Clinical Best Practices
- Utilize NAC for its mucolytic and anti-inflammatory properties in mucin-related conditions.
- Monitor for excessive mucin leading to corneal damage.
References
- Baudouin et al, 2019
- Abelson et al, 2003
- Karpecki, 2022
- Swamynathan and Wells, 2020
- Shih et al, 2017
- Eghtedari et al, 2022
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.